Inactive Instrument

Highlights Lannett Company, Inc.

Stocks

LCI

US5160122009

Pharmaceuticals

Highlights

08-31	Lannett Company LLC Launches Generic Version Of Advair Diskus In The US	CI
07-11	Lannett Company Recalls Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate Extended-Release Capsules Due To Label Mix-Up	CI
06-29	Aurobindo Pharma USA, Inc. completed the acquisition of Lannett Company, Inc.	CI
06-25	Aurobindo Pharma Limited and Lannett Company Inc Federal Trade Commission Proposes Settlement Requiring Divestiture of Generic Drug Products	CI
05-30	Lannett Company, Inc Recalls Primidone Tablets USP 250mg Due To Cross Contamination	CI
30/07/25	Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million.	CI
16/05/23	Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
04/04/23	Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	CI
02/02/23	Earnings Flash (LCI) LANNETT COMPANY Reports Q2 Revenue $80.9M	MT
02/02/23	Earnings Flash (LCI) LANNETT COMPANY Posts Q2 Loss $-0.34	MT
02/02/23	Lannett Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
02/02/23	Lannett Company, Inc. Raises Earnings Guidance for the Fiscal Year 2023	CI
26/01/23	Lannett to Implement 1-for-4 Reverse Stock Split	MT
04/01/23	Lannett Company Provides Development Update on Biosimilar Insulin Products	CI
03/11/22	Earnings Flash (LCI) LANNETT COMPANY Posts Q1 Loss $-0.42	MT
03/11/22	Earnings Flash (LCI) LANNETT COMPANY Reports Q1 Revenue $75.1M	MT
03/11/22	Lannett Company, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
03/11/22	Lannett Company, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023	CI
21/10/22	Lannett Company, Inc. Receives FDA Approval to Manufacture Numbrino® at Seymour Plant	CI
19/10/22	Lannett Sells Several Discontinued New Drug Applications to Unnamed Company for $3 Million	MT
31/08/22	Lannett Company, Inc. Announces Subject Dosing Complete for Pivotal Clinical Trial of Biosimilar Insulin Glargine	CI
25/08/22	Lannett Co Q4 Loss Widens Amid Lower Revenue, Issues Guidance	MT
25/08/22	Earnings Flash (LCI) LANNETT COMPANY Reports Q4 Loss $-0.44	MT
25/08/22	Earnings Flash (LCI) LANNETT COMPANY Posts Q4 Revenue $74.2M	MT
25/08/22	Lannett Company, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	CI